3 Trends In 2024 Cell Therapy Development, Q&A With Tenaya Therapeutics' CSO, Inside BlueRock Therapeutics' Parkinson's Disease Trial
Cell & Gene
The most valuable resource for professionals who make their living in the cell & gene therapies industry.
TRENDING CONTENT - Catch Up
Erin Harris breaks down three trends driving development in cell therapy in 2024. She discusses Alliance for Regenerative Medicine ’s Sector Snapshot for April 2024, highlighting advancements in blood cancer treatments, strides in tackling solid tumors, and promising new therapies for autoimmune diseases.
Tenaya Therapeutics ' CSO, Tim Hoey explains how the company's gene therapy may treat heart diseases like arrhythmogenic right ventricular cardiomyopathy (ARVC). They use AAV9-based vectors to deliver functional genes to heart cells, potentially providing curative treatment with a single dose. Learn how Tenaya's innovative approach could transform heart disease treatment and their progress toward clinical trials.
Would you ever need to follow GMP standards in workspaces where GMP is not required or possible? This article digs into why, when, and how to follow the principles of GMP.
BlueRock Therapeutics ' SVP Head of Development, Dr. Ahmed Enayetallah , joins Cell & Gene: The Podcast Host, Erin Harris , to discuss the company's phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months.
Exosomes derived from mesenchymal stem cells (MSC) are a novel and trending alternative to restoring tissues and organs, avoiding the limitations typically associated with stem cell therapy. According to Pubmed, the number of citations on exosome research has grown more than ten times in the last decade! Application scientist, Dr. Jorge Luis Escobar Ivirico , explains and underscores the key differences with the production of exosomes from other cellular therapies in an interview with Cell & Gene Therapy Insights.
领英推荐
On Feb. 6, 2024, new legislation was introduced in the House of Representatives: the FDA Modernization Act 3.0. It aims to reduce and replace the use of animals in nonclinical research, improve predictivity of nonclinical testing, and potentially reduce drug development times. This article shares an overview.
CELL & GENE: THE PODCAST - Listen Here
“We have what we call a Cell+Gene platform. Not only can you make fresh, healthy cells to replace lost cells or damaged cells, you can actually modify them or enhance them in a way that makes sense based on the disease we are trying to target.” - Dr. Ahmed Enayetallah , SVP Head of Development, BlueRock Therapeutics
CELL & GENE LIVE! - Register Now
Genome editing holds immense promise for treating genetic diseases, but off-target effects remain a significant concern. To ensure the safety and efficacy of genome editing therapies, researchers are developing various strategies to reduce off-target effects.
Join Cell & Gene 's Erin Harris , as she welcomes Oscar Segurado, MD, PhD , CMO at ASC Therapeutics , and Steven Kanner , Ph.D., CSO, Caribou Biosciences , where they will discuss the strengths and limitations of gene editing systems and highlight strategies to improve the safety of off-target assessment.?